Assessing, Counseling, and Treating Patients at High Risk for Breast Cancer

Edward Clifford, Kevin S. Hughes, Maegan Roberts, Sara Pirzadeh-Miller, Sarah A. McLaughlin

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Identifying patients at high risk of carrying pathogenic variants in genes is a crucial part of providing both accurate counseling and evidence-based treatment recommendations. Current risk assessment models have strengths and weaknesses that may limit their applicability to specific clinical circumstances. Clinicians must have knowledge regarding variations in available models, how they should be used, and what data they can expect from specific models. In addition, indications for genetic testing are expanding, and the adoption of next-generation sequencing has allowed the creation of multigene testing panels. Complex consequences of panel testing have included an increase in the incidence of identifying variants of uncertain significance and the identification of pathogenic variants in genes for which treatment guidelines are not available. Women diagnosed with breast cancer who carry pathogenic variants in genes with proven associations with breast cancer (BRCA1/2) or highly likely associations (PTEN, PALB2) require additional risk assessment to facilitate treatment decisions that will limit in-breast tumor recurrence and contralateral breast cancer.

Original languageEnglish (US)
Pages (from-to)1-5
Number of pages5
JournalAnnals of Surgical Oncology
DOIs
StateAccepted/In press - Jul 11 2016

Fingerprint

Counseling
Breast Neoplasms
Genes
Genetic Testing
Therapeutics
Guidelines
Recurrence
Incidence

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Clifford, E., Hughes, K. S., Roberts, M., Pirzadeh-Miller, S., & McLaughlin, S. A. (Accepted/In press). Assessing, Counseling, and Treating Patients at High Risk for Breast Cancer. Annals of Surgical Oncology, 1-5. https://doi.org/10.1245/s10434-016-5399-5

Assessing, Counseling, and Treating Patients at High Risk for Breast Cancer. / Clifford, Edward; Hughes, Kevin S.; Roberts, Maegan; Pirzadeh-Miller, Sara; McLaughlin, Sarah A.

In: Annals of Surgical Oncology, 11.07.2016, p. 1-5.

Research output: Contribution to journalArticle

Clifford, Edward ; Hughes, Kevin S. ; Roberts, Maegan ; Pirzadeh-Miller, Sara ; McLaughlin, Sarah A. / Assessing, Counseling, and Treating Patients at High Risk for Breast Cancer. In: Annals of Surgical Oncology. 2016 ; pp. 1-5.
@article{1000cb1e1a14490baad7e785d31cdfe4,
title = "Assessing, Counseling, and Treating Patients at High Risk for Breast Cancer",
abstract = "Identifying patients at high risk of carrying pathogenic variants in genes is a crucial part of providing both accurate counseling and evidence-based treatment recommendations. Current risk assessment models have strengths and weaknesses that may limit their applicability to specific clinical circumstances. Clinicians must have knowledge regarding variations in available models, how they should be used, and what data they can expect from specific models. In addition, indications for genetic testing are expanding, and the adoption of next-generation sequencing has allowed the creation of multigene testing panels. Complex consequences of panel testing have included an increase in the incidence of identifying variants of uncertain significance and the identification of pathogenic variants in genes for which treatment guidelines are not available. Women diagnosed with breast cancer who carry pathogenic variants in genes with proven associations with breast cancer (BRCA1/2) or highly likely associations (PTEN, PALB2) require additional risk assessment to facilitate treatment decisions that will limit in-breast tumor recurrence and contralateral breast cancer.",
author = "Edward Clifford and Hughes, {Kevin S.} and Maegan Roberts and Sara Pirzadeh-Miller and McLaughlin, {Sarah A.}",
year = "2016",
month = "7",
day = "11",
doi = "10.1245/s10434-016-5399-5",
language = "English (US)",
pages = "1--5",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",

}

TY - JOUR

T1 - Assessing, Counseling, and Treating Patients at High Risk for Breast Cancer

AU - Clifford, Edward

AU - Hughes, Kevin S.

AU - Roberts, Maegan

AU - Pirzadeh-Miller, Sara

AU - McLaughlin, Sarah A.

PY - 2016/7/11

Y1 - 2016/7/11

N2 - Identifying patients at high risk of carrying pathogenic variants in genes is a crucial part of providing both accurate counseling and evidence-based treatment recommendations. Current risk assessment models have strengths and weaknesses that may limit their applicability to specific clinical circumstances. Clinicians must have knowledge regarding variations in available models, how they should be used, and what data they can expect from specific models. In addition, indications for genetic testing are expanding, and the adoption of next-generation sequencing has allowed the creation of multigene testing panels. Complex consequences of panel testing have included an increase in the incidence of identifying variants of uncertain significance and the identification of pathogenic variants in genes for which treatment guidelines are not available. Women diagnosed with breast cancer who carry pathogenic variants in genes with proven associations with breast cancer (BRCA1/2) or highly likely associations (PTEN, PALB2) require additional risk assessment to facilitate treatment decisions that will limit in-breast tumor recurrence and contralateral breast cancer.

AB - Identifying patients at high risk of carrying pathogenic variants in genes is a crucial part of providing both accurate counseling and evidence-based treatment recommendations. Current risk assessment models have strengths and weaknesses that may limit their applicability to specific clinical circumstances. Clinicians must have knowledge regarding variations in available models, how they should be used, and what data they can expect from specific models. In addition, indications for genetic testing are expanding, and the adoption of next-generation sequencing has allowed the creation of multigene testing panels. Complex consequences of panel testing have included an increase in the incidence of identifying variants of uncertain significance and the identification of pathogenic variants in genes for which treatment guidelines are not available. Women diagnosed with breast cancer who carry pathogenic variants in genes with proven associations with breast cancer (BRCA1/2) or highly likely associations (PTEN, PALB2) require additional risk assessment to facilitate treatment decisions that will limit in-breast tumor recurrence and contralateral breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=84978148222&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978148222&partnerID=8YFLogxK

U2 - 10.1245/s10434-016-5399-5

DO - 10.1245/s10434-016-5399-5

M3 - Article

C2 - 27401444

AN - SCOPUS:84978148222

SP - 1

EP - 5

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

ER -